Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

This trial compares two approaches to treating colorectal cancer that has spread to the liver: standard chemotherapy (FOLFOX) alone versus FOLFOX combined with two additional drugs — serplulimab (an immunotherapy) and bevacizumab (a drug that blocks tumor blood vessel growth). The goal is to shrink tumors enough that they can be surgically removed. **You may be eligible if...** - You are between 18 and 75 years old - You have colorectal cancer that has spread only to the liver (up to 5 spots) with no spread elsewhere - Your tumor has been tested and is RAS wild-type, BRAF wild-type, and has a specific marker (pMMR/MSS) - Your primary colorectal tumor has been or can be removed with surgery - Your liver tumors are considered resectable (removable) or treatable with ablation - You have not had prior treatment for the liver metastases - Your blood counts and organ function are adequate **You may NOT be eligible if...** - You have cancer spread outside the liver - You have autoimmune conditions or prior serious immune-related side effects - You are pregnant or breastfeeding - You have active hepatitis B or C Talk to your doctor to see if this trial is right for you.